Frontlight ResearchEarly access
Taking people in United StatesNo phase
Patient Specific Talus Spacer Post Approval Study
Key facts
- Who runs it
- Paragon 28
- Where
- Baltimore, Charleston, Fort Wayne, Pearland, and Santa Rosa, United StatesSee the 5 sites
- Trial code
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 8 Jul 2022
- Expected to end
- 30 Nov 2033
- Type of study
- Observational
- Treatments tested
- Patient Specific Talus Spacer
- Record updated
- 16 September 2026
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Subject plans to undergo implantation of the Patient Specific Talus Spacer for avascular necrosis of the ankle joint independent of this research protocol
- Avascular necrosis of the ankle joint
- Age 21 years old or older
- Subject has good general health; and
- Subject signs a written informed consent form (ICF) prior to the surgical procedure
Who cannot take part
- Is currently participating in an investigational therapy (device and/or pharmaceutical) within 30 days prior to entering the study or such treatment is planned during the time course of follow-up
- Active systemic disease, such as AIDS, HIV, or active infection
- Active infection or the skin is compromised at the surgical site; and
- Systemic disease that would affect the subject's welfare
- Presence of any contraindication identified in the device Instructions for Use
- Surgeon determines that the patient is not appropriate for the Talus Spacer procedure based on the device IFU (including the enumerated Warnings and Precautions)
- Based on the medical opinion of the surgeon, the patient is not appropriate for the Talus Spacer procedure
- For female subjects, pregnancy
- Is a prisoner, incarcerated, or has been coerced to participate in the study that could impact the validity of results
- If the Sponsor has notified the site that 30 subjects have been enrolled in the study with a Cobalt Chromium Patient Specific Talus Spacer, and the surgeon believes that a Cobalt Chromium Patient Specific Talus Spacer is the best option for the patient
- If the Sponsor has notified the site that 30 subjects have been enrolled in the study with a Titanium (Ti6Al4V) with Titanium Nitride (TiN) coating Patient Specific Talus Spacer, and the surgeon believes that a Titanium (Ti6Al4V) with Titanium Nitride (TiN) coating Patient Specific Talus Spacer is the best option for the patient
Where in United States
- Mercy Institute for Foot & Ankle ReconstructionBaltimore, United StatesContact: Katherine ConveryTaking people
- Medical University of South CarolinaCharleston, United StatesContact: Hana HashiokaTaking people
- Fort Wayne OrthopedicsFort Wayne, United StatesContact: Faith Etherington, PA-CTaking people
- UT Physicians Orthopedics - PearlandPearland, United StatesContact: Jordan HarmonTaking people
- Sutter Health Santa RosaSanta Rosa, United StatesContact: Thomas Chang, DPMTaking people
About the trial
What the trial wants to find out
Humanitarian Device Exemption Approved Patient Specific Talus Spacer Post Approval Study.
The group in the trial
- 50 Subjects
50 Subjects Receiving the Patient Specific Talus Spacer.
Treatment: Patient Specific Talus Spacer
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 16 September 2026